Trials / Completed
CompletedNCT01259323
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Extrinsic Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the Safety and Tolerability of REGN668 (how the body reacts to the drug) compared to placebo (an inert substance) in patients with moderate-to-severe extrinsic Atopic Dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | REGN668 | Dose 1: REGN668 or placebo |
| BIOLOGICAL | REGN668 | Dose 2: REGN668 or placebo |
| BIOLOGICAL | REGN668 | Dose 3: REGN668 or placebo |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-07-01
- Completion
- 2012-07-01
- First posted
- 2010-12-14
- Last updated
- 2012-10-04
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01259323. Inclusion in this directory is not an endorsement.